title: Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.
abstract: Because of their neuroprotective properties, cannabinoids are being investigated in neurodegenerative disorders, mainly in preclinical studies. These disorders also include amyotrophic lateral sclerosis (ALS), a degenerative disease produced by the damage of the upper and lower motor neurons leading to muscle denervation, atrophy and paralysis. The studies with cannabinoids in ALS have been conducted exclusively in a transgenic mouse model bearing mutated forms of human superoxide dismutase-1, the first gene that was identified in relation with ALS. The present study represents the first attempt to investigate the endocannabinoid system in an alternative model, the transgenic mouse model of TAR-DNA binding protein-43 (TDP-43), a protein related to ALS and also to frontotemporal dementia. We used these mice for behavioral and histological characterization at an early symptomatic phase (70-80 days of age) and at a post-symptomatic stage (100-110 days of age). TDP-43 transgenic mice exhibited a worsened rotarod performance at both disease stages. This was accompanied by a loss of motor neurons in the spinal cord (measured by Nissl staining) and by reactive microgliosis (measured by Iba-1 immunostaining) at the post-symptomatic stage. We also detected elevated levels of the CB2 receptor (measured by qRT-PCR and western blotting) in the spinal cord of these animals. Double-staining studies confirmed that this up-regulation occurs in microglial cells in the post-symptomatic stage. Some trends towards an increase were noted also for the levels of endocannabinoids, which in part correlate with a small reduction of FAAH. Some of these parameters were also analyzed in the cerebral cortex of TDP-43 transgenic mice, but we did not observe any significant change, in agreement with the absence of anomalies in cognitive tests. In conclusion, our data support the idea that the endocannabinoid signaling system, in particular the CB2 receptor, may serve for the development of a neuroprotective therapy in TDP-43-related disorders. We are presently engaged in pharmacological experiments to investigate this possibility.
authors.affiliation: Instituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular III, Facultad de Medicina, Universidad Complutense, Madrid, 28040, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Espejo-Porras
authors.forename: Fabiana
authors.initials: F
authors.lastname: Piscitelli
authors.forename: Roberta
authors.initials: R
authors.lastname: Verde
authors.forename: José A
authors.initials: JA
authors.lastname: Ramos
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Di Marzo
authors.forename: Eva
authors.initials: E
authors.lastname: de Lago
authors.forename: Javier
authors.initials: J
authors.lastname: Fernández-Ruiz
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D002490:Central Nervous System / Q000187:drug effects / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D063388:Endocannabinoids / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D043885:Receptor, Cannabinoid, CB2 / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D004268:DNA-Binding Proteins; D063388:Endocannabinoids; D018696:Neuroprotective Agents; D043885:Receptor, Cannabinoid, CB2
references.citation: Hum Mol Genet. 2010 Apr 15;19(R1):R46-64
references.pmid: 20400460
references.citation: Brain Res. 2012 Jun 26;1462:26-39
references.pmid: 22608070
references.citation: Brain Res. 2012 Jun 15;1460:88-95
references.pmid: 22578468
references.citation: Br J Pharmacol. 2010 Jun;160(3):467-79
references.pmid: 20590558
references.citation: Pediatr Res. 2008 Dec;64(6):653-8
references.pmid: 18679164
references.citation: Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):689-93
references.pmid: 7846037
references.citation: Nat Rev Neurosci. 2013 Apr;14(4):248-64
references.pmid: 23463272
references.citation: CNS Neurosci Ther. 2014 Sep;20(9):809-15
references.pmid: 24703394
references.citation: Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18809-14
references.pmid: 19833869
references.citation: RNA Biol. 2010 Jul-Aug;7(4):420-9
references.pmid: 20639693
references.citation: Anal Biochem. 2013 Feb 15;433(2):105-11
references.pmid: 23085117
references.citation: Nature. 1993 Mar 4;362(6415):59-62
references.pmid: 8446170
references.citation: Nature. 2002 Aug 1;418(6897):530-4
references.pmid: 12152079
references.citation: J Neurochem. 2007 Apr;101(1):87-98
references.pmid: 17241118
references.citation: J Neurochem. 2004 Jun;89(6):1555-7
references.pmid: 15189359
references.citation: Behav Brain Res. 2009 Mar 2;198(1):58-68
references.pmid: 19022298
references.citation: Antioxid Redox Signal. 2009 Jul;11(7):1587-602
references.pmid: 19413484
references.citation: Eur J Pharmacol. 2006 Aug 7;542(1-3):100-5
references.pmid: 16781706
references.citation: Nat Rev Neurol. 2011 Oct 11;7(11):639-49
references.pmid: 21989247
references.citation: Expert Opin Ther Targets. 2010 Apr;14(4):387-404
references.pmid: 20230193
references.citation: J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1135-40
references.pmid: 20498181
references.citation: FASEB J. 2006 May;20(7):1003-5
references.pmid: 16571781
references.citation: Nat Rev Neurol. 2013 Nov;9(11):617-28
references.pmid: 24126629
references.citation: Expert Opin Emerg Drugs. 2011 Sep;16(3):537-58
references.pmid: 21806316
references.citation: Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Sep;6(3):182-4
references.pmid: 16183560
references.citation: Int J Exp Pathol. 2013 Feb;94(1):56-64
references.pmid: 23317354
references.citation: Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Mar;5(1):33-9
references.pmid: 15204022
references.citation: Nat Rev Neurol. 2011 Nov;7(11):616-30
references.pmid: 22051914
references.citation: BMC Neurol. 2006 Mar 02;6:12
references.pmid: 16512913
references.citation: Trends Neurosci. 2013 Aug;36(8):450-9
references.pmid: 23746459
references.citation: Science. 1992 Dec 18;258(5090):1946-9
references.pmid: 1470919
references.citation: Biochem J. 1997 Mar 1;322 ( Pt 2):671-7
references.pmid: 9065792
references.citation: Trends Pharmacol Sci. 2007 Jan;28(1):39-45
references.pmid: 17141334
references.citation: Nat Neurosci. 2014 Jan;17 (1):17-23
references.pmid: 24369373
references.citation: Hum Mol Genet. 2013 Oct 15;22(R1):R77-87
references.pmid: 23900071